TG02

Ligand id: 9095

Name: TG02

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 50.28
Molecular weight 372.2
XLogP 4.29
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
TG02 is being evaluated in Phase I clinical trials for chronic lymphocytic leukemia or small lymphocytic lymphoma (NCT01699152; dose ranging study) and advanced hematological malignancies (NCT01204164; dose-escalation study with arms investigating TG02 as a monotherapy, in combination with carfilzomib and dexamethasone in multiple myeloma patients and in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01204164 Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies Phase 1 Interventional Tragara Pharmaceuticals, Inc.
NCT01699152 Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Phase 1 Interventional Tragara Pharmaceuticals, Inc.